Related references
Note: Only part of the references are listed.CHARGE STATES OF DEFERASIROX-FERRIC IRON COMPLEXES
Robert C. Hider
AMERICAN JOURNAL OF KIDNEY DISEASES (2010)
Cystatin C levels in patients with β-thalassemia during deferasirox treatment
Ioannis Papassotiriou et al.
BLOOD CELLS MOLECULES AND DISEASES (2010)
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
Maria Domenica Cappellini et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Fanconi Syndrome Due to Deferasirox
Cedric Rafat et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study
Ali Taher et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Hypocalcemia in a dialysis patient treated with deferasirox for iron overload
Bushra Yusuf et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2008)
Acute interstitial nephritis due to deferasirox: a case report
Godela Brosnahan et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
Deferasirox for transfusion-related iron overload: A clinical review
Wesley T. Lindsey et al.
CLINICAL THERAPEUTICS (2007)
Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells
Bartosz Grzywacz et al.
BLOOD (2006)
Deferasirox - An oral agent for chronic iron overload
Heidi E. VanOrden et al.
ANNALS OF PHARMACOTHERAPY (2006)